Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**DIBNEPAN** is an oral fixed-dose capsule developed for neuropathic pain, including diabetic neuropathic pain and diabetic peripheral neuropathy. It contains bio-optimized palmitoylethanolamide, diacerein, and biochanin A. The sponsor attributes its anti-inflammatory and analgesic activity principally to palmitoylethanolamide-mediated activation of peroxisome proliferator-activated receptor alpha, with associated suppression of mast-cell degranulation, oxidative stress, and inflammatory enzyme activity. ([biokindle.com](https://www.biokindle.com/products-biokindle/dibnepan/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DIBNEPAN.